Conatus Pharmaceuticals (CNAT) Short Interest Ratio & Short Volume

Short interest is the volume of Conatus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 130,700 shares of CNAT short. 0.41% of Conatus Pharmaceuticals' shares are currently sold short. Learn More on Conatus Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.41% of Conatus Pharmaceuticals' floating shares are currently sold short.

Conatus Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 130,700 shares, a decrease of 10.5% from the previous total of 146,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Conatus Pharmaceuticals currently has issued a total of 33,170,000 shares. Some of Conatus Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Conatus Pharmaceuticals currently has a public float of 32,190,000 shares.

0.41% of Conatus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Conatus Pharmaceuticals: Monopar Therapeutics Inc. (2.01%), Purple Biotech Ltd. (0.93%), Imunon, Inc. (4.96%), Eterna Therapeutics Inc. (1.35%), Galera Therapeutics, Inc. (6.52%), RedHill Biopharma Ltd. (2.51%), Guardion Health Sciences, Inc. (14.39%), Moleculin Biotech, Inc. (1.24%), MIRA Pharmaceuticals, Inc. (0.43%), Elevai Labs, Inc. (0.32%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.57 billion), Match Group, Inc. ($3.08 billion), Wayfair Inc. ($2.66 billion), Tesla, Inc. ($2.60 billion), The Clorox Company ($2.52 billion), The Charles Schwab Co. ($2.39 billion), DexCom, Inc. ($2.39 billion), International Flavors & Fragrances Inc. ($1.88 billion), The Kroger Co. ($1.78 billion), and Snap Inc. ($1.66 billion). View all of the most shorted stocks.

Short selling CNAT is an investing strategy that aims to generate trading profit from Conatus Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Conatus Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNAT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNAT, twice per month. The most recent reporting period available is May, 15 2020.